Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LVIVO-TaVec400

Cell therapy

Early Phase 1 Most advanced trial (none active)
1 Registered trials

What is LVIVO-TaVec400?

LVIVO-TaVec400 is a product given as a single-dose intravenous infusion. It is studied in relapsed or refractory systemic lupus erythematosus, relapsed or refractory IgG4-related disease, progressive multiple sclerosis, and relapsed or refractory myasthenia gravis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Therapy area
Immunology, Neurology
In trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07583030 Early Phase 1 Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) Withdrawn LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Progressive Multiple Sclerosis (PMS)Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)Relapsed/Refractory Myasthenia Gravis(r/r MS)Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE)

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.